Real stories. Real impact. A better world.
GOOD NEWS DAILY
AllAnimalsCommunityEconomyEnvironmentHealthHumanityInnovationScienceWeekly Recap

High-dose vitamin B3 shows early promise against glioblastoma in a small Calgary trial

In a University of Calgary trial, 82% of 24 glioblastoma patients given high-dose niacin with standard treatment had no cancer progression after six months, against about 54% in earlier studies. The trial is small and has no control group.

By , Editor

· Canada · 3 min read

Source: University of Calgary ↗
Share
A hospital treatment room with a ring-shaped scanner and a patient table under green-tinted lighting
A hospital treatment room with a ring-shaped scanner and a patient table under green-tinted lighting. Photo: jarmoluk (Pixabay)

Of 24 patients with glioblastoma who took high-dose vitamin B3 alongside standard treatment, 82% showed no progression of their cancer after six months, the University of Calgary reported. That is 28 percentage points better than in earlier studies, the researchers say. The results are interim findings from a small Phase I-II trial.

The study is led by oncologist Gloria Roldan Urgoiti and neuroscientist Wee Yong of the university's Cumming School of Medicine, both members of the Hotchkiss Brain Institute and the Arnie Charbonneau Cancer Institute.

Nearly half of patients see their tumor grow again within six months

Glioblastoma is usually treated with surgery to remove as much of the tumor as possible, followed by radiation and the chemotherapy drug temozolomide. Even so, the cancer comes back. With that standard care, patients survive about 15 months, and only 53.9% are free of progression at six months, according to the trial paper in the Journal of Neuro-Oncology.

“Glioblastoma is the most aggressive brain cancer in adults. Survival of patients with this condition hasn’t changed significantly for 20 years.” — Gloria Roldan Urgoiti, clinical associate professor, Cumming School of Medicine, University of Calgary

The idea is to wake up immune cells the tumor has disarmed

The approach began in Yong's lab. In a 2020 study in Science Translational Medicine, his team reported that niacin reactivated monocytes and macrophages, immune cells that glioblastoma normally renders ineffective. In mice with brain tumors grown from patients' cells, niacin reduced tumor size and prolonged survival, and combining it with temozolomide extended survival further.

"Normally, the immune system will try to counter and prevent tumour growth; however, this brain cancer supresses the immune system," Yong said in the university's statement. "Niacin treatment rejuvenates immune cells so they can do what they are supposed to do, attack and kill the cancer cells."

In the trial, patients receive controlled-release niacin on top of chemotherapy and radiotherapy. One of them, Edward Waldner, was 55 when a scan found the tumor. "When I left the hospital after surgery I was told, that's it, that's all we can do," he told the university. He now hopes to hear the word "stable" at his regular scans.

Doctors found a safe dose of 2,000 mg a day

The first phase of the trial, with 15 patients, raised the niacin dose step by step from 500 to 3,000 mg a day. The most common side effect was flushing, seen in 10 of the 15 patients and mostly mild. Two patients had serious side effects at 2,500 mg, one affecting blood platelets and one raising bilirubin, so the team set 2,000 mg a day as the maximum tolerated dose, the paper says.

The team had agreed in advance to stop the study if niacin failed to raise six-month progression-free survival by at least 20 points over older studies. The interim result, 82.3% based on central review of scans, cleared that bar. Other teams are looking at how to keep the immune system fighting tumors longer, for example by blocking the molecule MEK so that T cells don't burn out, so far in lab and mouse studies.

The comparison is with historical patients, not with a control group in the same trial, and 24 people is a small sample. Progression-free survival at six months also says nothing yet about overall survival. The researchers warn that high doses of vitamins such as niacin can be toxic and should be taken only under medical supervision. A final analysis of 48 participants is expected by the end of 2026 or early 2027. The work is funded by the Canadian Institutes of Health Research and the Alberta Cancer Foundation.

Not medical advice. This article reports on research and health programs for general information. Results from early studies often change in larger trials. Talk to a doctor before making decisions about your own health or treatment.

Sources

How we choose and verify sources: editorial policy.

More stories: Good news from clinical trials (16) →

Explainer: What are the phases of a clinical trial? →

Your weekly dose of good news

The 5 biggest positive stories of the week, straight to your inbox. Free, no noise.